Clinical trial
Immunotherapy of Stage III/IV Melanoma Patients
NCT00112242 · Centre Hospitalier Universitaire Vaudois, Other · Completed
Key facts
| NCT number | NCT00112242 |
|---|---|
| Title | Immunotherapy of Stage III/IV Melanoma Patients |
| Official title | Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant |
| Lead sponsor | Centre Hospitalier Universitaire Vaudois, Other |
| Collaborators | Ludwig Institute for Cancer Research |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Melan-A ELA + Montanide, Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide, Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG, Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG, Melan-A-EAA/ELA + NY-ESO-1 lp + MAGE-A10 + Montanide + CpG+ IL-2 |
| Enrollment | 39 |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Jun 1, 2005 |
| Last update posted | Jun 18, 2020 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: